New Technologies

Transgenic animals to obtain therapeutic recombinant human proteins | new technologies

Biosidus S.A. has developed a patent protected technological platform based on the generation of genetically modified bovines by mammal cloning techniques. Biosidus first achievement in its Pharmaceutical Dairy Project was to produce somatropin (recombinant human growth hormone) in the milk of transgenic cows. BE studies have been completed and comparative clinical trials against innovator are projected.


Based on the performance of this technological platform Biosidus S.A. has developed transgenic cows to produce functional food. Functional food is defined as modified food that claims to improve health or well-being by providing benefit beyond that of the traditional nutrients it contains.

Biosidus is focusing its R&D efforts on the development of transgenic animals to produce milk containing nanoantibodies derived from heavy chain immunoglobulins against Rotavirus. These antibodies have the capacity to neutralize Rotavirus, etiological agent of gastrointestinal infections which are the main cause of infantile morbi-mortality in Argentina and other emerging countries. The selection of milk as a vehicle of these therapeutic antibodies relies on its wide spread consumption in the paediatric population which is in turn the most susceptible to Rotavirus infection.

This technological platform can be applied to other developments to obtain milks with nanoantibodies capable of neutralizing other infectious agents.


International Presence

  • With more than two decades of expertise in the manufacture and distribution of high quality biosimilar products in emerging market countries, a strong portfolio and pipeline of products, significant development and manufacturing capabilities and an established network of distribution partners, we believe we are well positioned to take advantage of opportunities for growth in the global biosimilar therapeutics market

    / More